Autologous hematopoietic stem cell transplantation(auto-HSCT)is the standard salvage strategy for young patients with Hodgkin lymphoma(HL)who have failed induction therapy or relapse after remission and is effective in nearly 50％of cases.The quality of response at the time of transplantation is most relevant to prognosis,and patients in complete remission have better outcomes.Therefore,the first-line salvage regimen to be applied prior to transplantation needs to be balanced with the need to produce high-quality efficacy without excessive myelotoxicity and without compromising peripheral blood stem cell mobilization.In this sense,the addition of newer agents that are effective in HL,such as brentuximab vedotin and anti-programmed death 1 antibodies,to conventional treatment regimens may help improve the rate of complete response.Optimizing conditioning regimen and application of a post-autologous consolidate therapy are two important ways to improve the transplant outcome especially for those who show high risk of the characteristics of early recurrence or progression.In this article,the factors related to the efficacy of auto-HSCT in HL patients are reviewed,aiming to improve the prognosis of patients who have a high risk of post-auto-HSCT failure.
维普
万方数据